The inhibitory role of adiponectin in angiogenesis has been demonstrated in multiple types of cancer, including fibrosarcoma (Bråkenhielm et al., 2004), hepatocellular carcinoma (Man et al., 2010), renal cell carcinoma (Kleinmann et al., 2014), basal cell breast cancer (Dubois et al., 2013), and prostate cancer (Gao et al., 2015). The gene discussed is ADIPOQ; the disease is prostate cancer.